The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial

Tumor–stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients

(2010) Esther M. de Kruijf et al.   BREAST CANCER RESEARCH AND TREATMENT

The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients

(2010) N P West et al.   BRITISH JOURNAL OF CANCER

The stromal part of adenocarcinomas of the oesophagus: Does it conceal targets for therapy?

(2010) Ewout F.W. Courrech Staal et al.   EUROPEAN JOURNAL OF CANCER

Phase III Randomized Trial Assessing Rofecoxib in the Adjuvant Setting of Colorectal Cancer: Final Results of the VICTOR Trial

(2010) Rachel S. Midgley et al.   JOURNAL OF CLINICAL ONCOLOGY

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

(2010) Daniel J. Sargent et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy

(2009) Seung Tae Kim et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803

(2009) Monica M. Bertagnolli et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial

(2008) John A Baron et al.   LANCET